Toutes les publications ci-jointes se referent à l’utilisation des kits Tracker en pratique clinique

TRACKER: S√©lection de publications sur l’adalimumab dans des revues √† comit√© de lecture
Roblin X, Williet N, Boschetti G, Phelip JM, Del Tedesco E, Berger AE, Vedrines P, Duru G, Peyrin-Biroulet L, Nancey S, Flourie B, Paul S Addition of Azathioprine to the Switch of anti-TNF in Patients With IBD in Clinical Relapse With Undetectable anti-TNF Trough Levels and Antidrug Antibodies: A Prospective Randomised Trial Gut. 2020 Jan 24. https://pubmed.ncbi.nlm.nih.gov/31980448/
Grossi V, Infantino M, Manfredi M, Basile U, Gulli F, Marino M, Li Gobbi F, Damiani A, Atzeni F, Benucci M. Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports. Clin Chem Lab Med. 2019 Oct 30 https://pubmed.ncbi.nlm.nih.gov/31665114/
Paul S, Roblin X. Letter: immunogenicity of anti-TNF in elderly IBD patients. Aliment Pharmacol Ther. 2019 Aug;50(3):336. https://pubmed.ncbi.nlm.nih.gov/31313368/
Little RD, Chu IE, van der Zanden EP, Flanagan E, Bell SJ, Gibson PR, Sparrow MP, Shelton E, Connor SJ, Roblin X, Ward MG. Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort analysis. J Crohns Colitis. 2019 May 15.  https://pubmed.ncbi.nlm.nih.gov/31094417/
Quistrebert J, H√§ssler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, D√∂nnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Bro√ęt P, Mariette X; ABIRISK Consortium. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. Semin Arthritis Rheum. 2018 Oct 12. pii: S0049-0172(18)30176-8.¬† https://pubmed.ncbi.nlm.nih.gov/30420245/
Labetoulle R, Roblin X, Paul S. Prolonged Persistence of Adalimumab Transferred From Mother to Infant During Pregnancy. Ann Intern Med. 2018 Mar 6. https://pubmed.ncbi.nlm.nih.gov/29507939/
Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F. Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases. Biologics: Targets and Therapy 2018:12 37‚Äď41 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797458/
Fay S, Ungar B, Paul S, Levartovsky A, Yavzori M, Fudim E, Picard O, Eliakim R, Ben-Horin S, Roblin X, Kopylov U. The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn’s Disease Treated with Tumor Necrosis Factor Inhibitors. Inflamm Bowel Dis. 2017 Aug 22.¬† https://pubmed.ncbi.nlm.nih.gov/28837524/
Gonczi L, Kurti Z, Rutka M, Vegh Z, Farkas K, Lovasz BD, Golovics PA, Gecse KB, Szalay B, Molnar T, Lakatos PL. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases. BMC Gastroenterol. 2017 Aug 8;17(1):97 https://pubmed.ncbi.nlm.nih.gov/28789636/
Johnston EL, Warner BD, Digby-Bell JL, Unsworth N, Anderson S, Sanderson J D, Arkir Z, Irving PM Utilisation of anti-TNF levels in a UK tertiary IBD centre. Frontline Gastroenterol. 2017 Jul;8(3):189-195. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558278/
Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR Irving PM. Infliximab and adalimumab drug levels in Crohn’s disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther. 2017 Jul;46(2):150-161.¬† https://pubmed.ncbi.nlm.nih.gov/28481014/
Mota F, Neves E, Oliveira JC, Selores M, Torres T. Importance of immunogenicity testing for cost-effective management of psoriasis patients treated with adalimumab. Acta Dermatovenerol Alp Pannonica Adriat. 2017 Jun;26(2):33-35. https://pubmed.ncbi.nlm.nih.gov/28632883/
Martelli L, Olivera P, Roblin X, Attar A3 Peyrin-Biroulet L4. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol. 2017 Jan;52(1):19-25.  https://pubmed.ncbi.nlm.nih.gov/27665099/
Ungar B, Kopylov U, Engel T,Yavzori M, Fudim E, Picard O, Lang A, Williet N, Paul S, Chowers Y, Bar-Gil Shitrit A, Eliakim A, Ben-Horin A,  Roblin X. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2017 Jan;45(2):276-282. https://pubmed.ncbi.nlm.nih.gov/27862102/
Vincent FB, Pavy S, Krzysiek R, Lequerré T, Sellam J, Taoufik Y, Mariette X, Miceli-Richard C. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.  Joint Bone Spine. 2016 Oct;83(5):595-7.  https://pubmed.ncbi.nlm.nih.gov/27066773/
Zufferey P, Perreau M, So A. High level of anti-drug antibodies after intra-articular injection of anti-TNF. Rheumatology (Oxford). 2015 Dec;54(12):2291-2 https://pubmed.ncbi.nlm.nih.gov/26320135/
Roblin X Attar A, Lamure M, Savarieau B, Brunel P, Duru G, Peyrin-Biroulet L. Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn’s disease patients who lose response to infliximab. Journal of Market Access & Health Policy, [S.l.], v. 3, oct. 2015.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802699/
Roblin X, Paul S. Letter: stool adalimumab detection in ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015 Jul;42(2):240. https://pubmed.ncbi.nlm.nih.gov/26081687/¬†
Ben-Horin S, Chowers Y, Ungar B, Kopylov U, Loebstein R, Weiss B, Eliakim R, Del Tedesco E, Paul S, Roblin X. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.  Aliment Pharmacol Ther. 2015 Aug;42(3):356-64. https://pubmed.ncbi.nlm.nih.gov/26032402/
Rinaudo-Gaujous M, Roblin X, Marotte H, Paul S. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015 Aug;74(8):e40.  https://pubmed.ncbi.nlm.nih.gov/25802246/
Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014 Jan;12(1):80-84.e2. https://pubmed.ncbi.nlm.nih.gov/23891927/
Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014 Aug;109(8):1250-6.  https://pubmed.ncbi.nlm.nih.gov/24913041/
Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol. 2013 Aug;169(2):306-13.  https://pubmed.ncbi.nlm.nih.gov/23550925/
TRACKER: Sélection de publications sur Certolizumab dans des revues à comité de lecture
Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Casteele N Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis Clin Transl Sci. 2020 Feb 26. https://pubmed.ncbi.nlm.nih.gov/32100960/
Grossi V, Infantino M, Manfredi M, Basile U, Gulli F, Marino M, Li Gobbi F, Damiani A, Atzeni F, Benucci M. Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports. Clin Chem Lab Med. 2019 Oct 30. https://pubmed.ncbi.nlm.nih.gov/31665114/
Paul S, Roblin X. Letter: immunogenicity of anti-TNF in elderly IBD patients. Aliment Pharmacol Ther. 2019 Aug;50(3):336.  https://pubmed.ncbi.nlm.nih.gov/31313368/
Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F. Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases. Biologics: Targets and Therapy 2018:12 37‚Äď41 https://www.dovepress.com/correlation-between-hla-haplotypes-and-the-development-of-antidrug-ant-peer-reviewed-article-BTT
Fay S, Ungar B, Paul S, Levartovsky A, Yavzori M, Fudim E, Picard O, Eliakim R, Ben-Horin S, Roblin X, Kopylov U. The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn’s Disease Treated with Tumor Necrosis Factor Inhibitors. Inflamm Bowel Dis. 2017 Aug 22.¬† https://pubmed.ncbi.nlm.nih.gov/28837524/
Johnston EL, Warner BD, Digby-Bell JL, Unsworth N, Anderson S, Sanderson J D, Arkir Z, Irving PM Utilisation of anti-TNF levels in a UK tertiary IBD centre. Frontline Gastroenterol. 2017 Jul;8(3):189-195. https://pubmed.ncbi.nlm.nih.gov/28839908/
Vincent FB, Pavy S, Krzysiek R, Lequerré T, Sellam J, Taoufik Y, Mariette X, Miceli-Richard C. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.  Joint Bone Spine. 2016 Oct;83(5):595-7.  https://pubmed.ncbi.nlm.nih.gov/27066773/
Zufferey P, Perreau M, So A. High level of anti-drug antibodies after intra-articular injection of anti-TNF. Rheumatology (Oxford). 2015 Dec;54(12):2291-2.  https://pubmed.ncbi.nlm.nih.gov/26320135/
TRACKER: Sélection de publications sur Etanercept dans des revues à comité de lecture
Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol. 2013 Aug;169(2):306-13. https://pubmed.ncbi.nlm.nih.gov/23550925/
TRACKER: Sélection de publications sur Golimumab dans des revues à comité de lecture
Berger AE, Duru G, de Vries A, Marini JC, Aoucheta D, Cornillie F, Nancey S, Detrez I, Gils A, Roblin X, Paul S. Comparison of immunoassays for measuring serum levels of golimumab and antibodies against golimumab in ulcerative colitis: a retrospective observational study. Ther Drug Monit. 2019 Feb 26.   https://pubmed.ncbi.nlm.nih.gov/30817702/
TRACKER: Sélection de publications sur Infliximab dans des revues à comité de lecture
Lauret A, Moltó A, Abitbol V, Gutermann L, Conort O, Chast F, Goulvestre C, Le Jeunne C, Chaussade S, Roux C, Batteux F, Dougados M, Allanore Y, Avouac J Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Semin Arthritis Rheum. 2020 Feb 19. https://pubmed.ncbi.nlm.nih.gov/32268935/
Roblin X, Williet N, Boschetti G, Phelip JM, Del Tedesco E, Berger AE, Vedrines P, Duru G, Peyrin-Biroulet L, Nancey S, Flourie B, Paul S Addition of Azathioprine to the Switch of anti-TNF in Patients With IBD in Clinical Relapse With Undetectable anti-TNF Trough Levels and Antidrug Antibodies: A Prospective Randomised Trial Gut. 2020 Jan 24. https://pubmed.ncbi.nlm.nih.gov/31980448/
Neveu B, Kunst  A, Prosser  C, Robitaille R An in Vitro Comparison of Four Different Immunoassays for the Monitoring of Infliximab Biosimilars Drug Levels Clin Biochem. 2020 Jan 23. https://pubmed.ncbi.nlm.nih.gov/31982376/
Petitdidier  N , Beaugerie  L , Carbonnel  F , Bourrier  A , Treton  X , Sylvie Rajca  S , Georgia Malamut  G , Abitbol  V , Allez  M , Pelletier  AL , Marthey  L, Jouet  P, Benamouzig  R, Amiot X , Bouhnik  Y , Amiot A, Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease Clin Res Hepatol Gastroenterol. 2020 Jan 7. https://europepmc.org/article/med/31924554
Valido A, Silva-Dinis J, Saavedra M, Iria I, Gonçalves J, Lopes JP, Fonseca JE. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center. Acta Reumatol Port. 2019 Nov 22. https://pubmed.ncbi.nlm.nih.gov/31754088/
Paul S, Roblin X. Letter: immunogenicity of anti-TNF in elderly IBD patients. Aliment Pharmacol Ther. 2019 Aug;50(3):336.  https://pubmed.ncbi.nlm.nih.gov/31313368/
Ungar B, Ben-Shatach Z, Ben-Haim G, Yavzori M, Picard O, Fudim E, Kopylov U, Veyrard P, Del Tedesco √Č, Paul S, Eliakim R, Ben-Horin S, Roblin X. Infliximab therapy intensification upon loss of response: Is there an optimal trough level? Dig Liver Dis. 2019 Mar 5.¬† https://pubmed.ncbi.nlm.nih.gov/30928420/
Ilias A, Szanto K, Gonczi L, Kurti Z, Golovics PA, Farkas K, Schafer E, Szepes Z, Szalay B, Vincze A, Szamosi T, Molnar T, Lakatos PL. Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade. Clin Gastroenterol Hepatol. 2019 Jan 7. https://pubmed.ncbi.nlm.nih.gov/30630103/
Attar A, Duru G, Roblin X, Savarieau B, Brunel P, Lamure M, Peyrin-Biroulet L. Cost savings using a test-based de-escalation strategy for patients with Crohn’s disease in remission on optimized infliximab: A discrete event model study. Dig Liver Dis. 2019 Jan;51(1):112-119. https://pubmed.ncbi.nlm.nih.gov/30268737/
Fernandes SR, Bernardo S, Sim√Ķes C, Gon√ßalves AR, Valente A, Baldaia C, Moura Santos P, Correia LA, Tato Marinho R. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Jun 27.¬† https://pubmed.ncbi.nlm.nih.gov/31247074/
Quistrebert J, H√§ssler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, D√∂nnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Bro√ęt P, Mariette X; ABIRISK Consortium. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. Semin Arthritis Rheum. 2018 Oct 12. pii: S0049-0172(18)30176-8.¬† https://pubmed.ncbi.nlm.nih.gov/30420245/
Jentzer A, -Emmanuelle Berger A, Labetoulle R, Haccourt A, Roblin X, Paul S. Short Communication: Evaluation of infliximab and anti-infliximab LISA-TRACKER immunoassays for the therapeutic drug monitoring of SB2 infliximab biosimilar. Ther Drug Monit. 2018 Sep 21.  https://europepmc.org/article/pmc/pmc5850768
Poullenot F, Nivet D, Paul S, Riviere P, Roblin X, Laharie D. Severe endoscopic lesions are not associated with more infliximab fecal loss in acute severe ulcerative colitis. Dig Liver Dis. 2018 Jul 10. https://pubmed.ncbi.nlm.nih.gov/30077467/
Nasser Y, Labetoulle R, Harzallah I, Berger AE, Roblin X, Paul S. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD. Dig Dis Sci. 2018 Jun 9.  https://pubmed.ncbi.nlm.nih.gov/29948562/
Dutzer D, Nasser Y, Berger AE, Roblin X, Paul S. Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients. Aliment Pharmacol Ther. 2018 Jun;47(11):1571-1573.  https://pubmed.ncbi.nlm.nih.gov/29878425/
Guidi L, Pugliese D, Panici Tonucci T, Berrino A, Tolusso B, Basile M, Cantoro L, Balestrieri P, Civitelli F, Bertani L, Marzo M, Felice C, Gremese E, Costa F, Viola F, Cicala M, Kohn A, Gasbarrini A, Rapaccini GL, Ruggeri M, Armuzzi A. Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. J Crohns Colitis. 2018 May 31. https://pubmed.ncbi.nlm.nih.gov/29860436/
Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F. Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases. Biologics: Targets and Therapy 2018:12 37‚Äď41. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797458/
Avouac J, Moltó A, Abitbol V, Etcheto A, Salcion A, Gutermann L, Klotz C, Elhai M, Cohen P, Soret PA, Morin F, Conort O, Chast F, Goulvestre C, Jeunne CL, Chaussade S, Kahan A, Roux C, Allanore Y, Dougados M. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2017 Oct 5.  https://pubmed.ncbi.nlm.nih.gov/29102156/
Fay S, Ungar B, Paul S, Levartovsky A, Yavzori M, Fudim E, Picard O, Eliakim R, Ben-Horin S, Roblin X, Kopylov U. The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn’s Disease Treated with Tumor Necrosis Factor Inhibitors. Inflamm Bowel Dis. 2017 Aug 22. https://pubmed.ncbi.nlm.nih.gov/28837524/
Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study. Inflamm Bowel Dis. 2017 Sep 22.  https://pubmed.ncbi.nlm.nih.gov/28945636/
Johnston EL, Warner BD, Digby-Bell JL, Unsworth N, Anderson S, Sanderson J D, Arkir Z, Irving PM Utilisation of anti-TNF levels in a UK tertiary IBD centre. Frontline Gastroenterol. 2017 Jul;8(3):189-195. https://pubmed.ncbi.nlm.nih.gov/28839908/
Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR Irving PM. Infliximab and adalimumab drug levels in Crohn’s disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther. 2017 Jul;46(2):150-161.¬† https://pubmed.ncbi.nlm.nih.gov/28481014/
Bor R, Farkas K, F√°bi√°n A, B√°lint A, Milassin √Ā, Rutka M, Matuz M, Nagy F, Szepes Z, Moln√°r T. Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease. PLoS One. 2017 Mar 31;12(3):e0172916.¬† https://pubmed.ncbi.nlm.nih.gov/28362851/
Dénarié D, Rinaudo-Gaujous M, Thomas T, Paul S, Marotte H. Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab. Mediators Inflamm. 2017 Epub 2017 Mar 2. https://pubmed.ncbi.nlm.nih.gov/28352145/
Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flouri√© B, Nancey S, Peyrin-Biroulet L, Paul S. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn’s Disease. Inflamm Bowel Dis. 2017 Jan;23(1):126-132. https://pubmed.ncbi.nlm.nih.gov/28002129/
Martelli L, Olivera P, Roblin X, Attar A3 Peyrin-Biroulet L4. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol. 2017 Jan;52(1):19-25.  https://pubmed.ncbi.nlm.nih.gov/27665099/
Gonczi L, Vegh Z, Golovics PA, Rutka M, Gecse KB, Bor R, Farkas K, Szamosi T, Bene L, Gasztonyi B, Krist√≥f T, Lakatos L, Miheller P, Palatka K, Papp M, Patai √Ā, Salamon √Ā, T√≥th GT, Vincze √Ā, Biro E, Lovasz BD, Kurti Z, Szepes Z, Moln√°r T, Lakatos PL. Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role? J Crohns Colitis. 2016 Nov 12. https://pubmed.ncbi.nlm.nih.gov/27838610/
Vincent FB, Pavy S, Krzysiek R, Lequerré T, Sellam J, Taoufik Y, Mariette X, Miceli-Richard C. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.  Joint Bone Spine. 2016 Oct;83(5):595-7.  https://pubmed.ncbi.nlm.nih.gov/27066773/
Lee MW, Connor S, Ng W, Toong CM. Comparison of infliximab drug measurement across three commercially available ELISA kits. Pathology. 2016 Aug 23.  https://pubmed.ncbi.nlm.nih.gov/27567230/
Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, Manfredi M, Parisi S, Fusaro E, Batticciotto A, Sarzi-Puttini P, Atzeni F, Meacci F. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.  Immunol Res. 2016 Jul 23.  https://pubmed.ncbi.nlm.nih.gov/27449503/
Gecse KB, Lov√°sz BD, Farkas K, Banai J, Bene L, Gasztonyi B, Golovics PA, Krist√≥f T, Lakatos L, Csontos √ĀA, Juh√°sz M, Nagy F, Palatka K, Papp M, Patai √Ā, Lakner L, Salamon √Ā, Szamosi T, Szepes Z, T√≥th GT, Vincze √Ā, Szalay B, Moln√°r T, Lakatos PL. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort. J Crohns Colitis. 2016 Feb;10(2):133-40.¬† https://pubmed.ncbi.nlm.nih.gov/26661272/
Zufferey P, Perreau M, So A. High level of anti-drug antibodies after intra-articular injection of anti-TNF. Rheumatology (Oxford). 2015 Dec;54(12):2291-2 https://pubmed.ncbi.nlm.nih.gov/26320135/
Coutzac C, Chapuis J, Poullenot F, Chabrun E, Capdepont M, Blanco P, Laharie D. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study. J Crohns Colitis. 2015 Nov;9(11):982-7.  https://pubmed.ncbi.nlm.nih.gov/26351388/
Schmitz EM, van de Kerkhof D, Hamann D, van Dongen JL, Kuijper PH, Brunsveld L, Scharnhorst V, Broeren MA. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med. 2015 Nov 20.  https://pubmed.ncbi.nlm.nih.gov/26587745/
Roblin X Attar A, Lamure M, Savarieau B, Brunel P, Duru G, Peyrin-Biroulet L. Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn’s disease patients who lose response to infliximab. Journal of Market Access & Health Policy, [S.l.], v. 3, oct. 2015.  https://pubmed.ncbi.nlm.nih.gov/27123185/
Paul S, Roblin X, Peyrin-Biroulet L. Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015 Oct;42(7):939-40. https://pubmed.ncbi.nlm.nih.gov/26331560/
Ben-Horin S, Chowers Y, Ungar B, Kopylov U, Loebstein R, Weiss B, Eliakim R, Del Tedesco E, Paul S, Roblin X. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.  Aliment Pharmacol Ther. 2015 Aug;42(3):356-64.  https://pubmed.ncbi.nlm.nih.gov/26032402/
Rinaudo-Gaujous M, Roblin X, Marotte H, Paul S. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015 Aug;74(8):e40.  https://pubmed.ncbi.nlm.nih.gov/25802246/
Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohns Colitis. 2015 Jul;9(7):525-31.  https://pubmed.ncbi.nlm.nih.gov/25895875/
Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013 Nov;19(12):2568-76. https://pubmed.ncbi.nlm.nih.gov/24013361/
TRACKER: Sélection de publications sur Rituximab dans des revues à comité de lecture
Boyer-Suavet S, Andreani M, Lateb M, Savenkoff B, Brglez V, Benzaken S, Bernard G, Nachman PH, Esnault V, SeitzPolski B. Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated with Rituximab Front Immunol. 2019; 10: 3069 https://pubmed.ncbi.nlm.nih.gov/31998325/
Combier A, Nocturne G, Henry J, Belkhir R, Pavy S, Le Tiec C, Descamps E, Seror R, Mariette X. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy. Rheumatology (Oxford). 2019 Oct 9.  https://pubmed.ncbi.nlm.nih.gov/31613955/
Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, Ticchioni M, Rosenthal A, Benzaken S, Bernard G, Lambeau G, Ronco P, Esnault VLM. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1173-1182.  https://pubmed.ncbi.nlm.nih.gov/31340979/
Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, Nachman P, Esnault V, Seitz-Polski B. Rituximab bioavailability in primary membranous nephropathy. Nephrol Dial Transplant. 2019 Mar 30. https://www.erknet.org/index.php?id=jwatch&theme=35&all=1
Einarsson JT, Evert M, Geborek P, Saxne T, Lundgren M, Kapetanovic MC. Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies. Clin Rheumatol. 2017 Dec;36(12):2743-2750. https://pubmed.ncbi.nlm.nih.gov/28980088/
TRACKER: Sélection de publications sur Tocilizumab dans des revues à comité de lecture
Bastida C, Ruiz-Esquide V, Pascal M, de Vries Schultink AHM, Yag√ľe J, Sanmart√≠ R, Huitema ADR, Soy D. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis. Br J Clin Pharmacol. 2018 Jan 4. https://pubmed.ncbi.nlm.nih.gov/29314183/
Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F. Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases. Biologics: Targets and Therapy 2018:12 37‚Äď41 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797458/
Benucci M, Meacci F, Grossi V, Infantino M, Manfredi M, Bellio E, Bellio V, Li Gobbi F, Bazzichi L, Moscato P, Caputo D, Saviola G, Talotta R, Sarzi-Puttini P, Atzeni F. Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. Biologics. 2016 Mar 11;10:53-8.  https://pubmed.ncbi.nlm.nih.gov/27041992/
TRACKER: Sélection de publications sur Ustekinumab dans des revues à comité de lecture
Painchart C, Brabant S, Duveau N, Nachury M, Desreumaux P, Branche J, G√©rard R, Prevost CLD, Wils P, Lambin T, Boualit M, Labalette M, Pariente B. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease. Dig Dis Sci. 2019 Oct 10.¬† https://pubmed.ncbi.nlm.nih.gov/31599389/
Soufflet N, Boschetti G, Roblin X, Cuercq C, Williet N, Charlois AL, Duclaux-Loras R, Danion P, Mialon A, Faure M, Paul S, Flourie B, Nancey S. Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2019 Mar 6.¬† https://pubmed.ncbi.nlm.nih.gov/30851477/
Toro-Montecinos M, Ballescá F, Ferrandiz C, Teniente-Serra A, Martinez-Caceres E, Carrascosa JM1. Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks. J Dermatolog Treat. 2018 May 10:1-5.  https://pubmed.ncbi.nlm.nih.gov/29683393/
TRACKER: Sélection de publications sur Vedolizumab dans des revues à comité de lecture
Guidi L, Pugliese D, Tonucci TP, Bertani L, Costa F, Privitera G, Tolusso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United European Gastroenterol J. 2019 Nov;7(9):1189-1197. Epub 2019 Sep 3. https://pubmed.ncbi.nlm.nih.gov/31700632/ 
Pouillon L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, Choukour M, Gauchotte G, Zallot C, Danese S, Baumann C, Peyrin-Biroulet L. Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. J Crohns Colitis. 2019 Jan 29.  https://pubmed.ncbi.nlm.nih.gov/30698684/
Paul S, Williet N, Di Bernado T, Berger AE, Boschetti G, Filippi J, Del Tedesco E, Nancey S, Flourie B, Roblin X. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study. J Crohns Colitis. 2018 May 31.  https://pubmed.ncbi.nlm.nih.gov/29860366/
Ben-Horin S, Ungar B, Kopylov U, Lahat A, Yavzori M, Fudim E, Picard O, Peled Y, Eliakim R, Del Tedesco E, Paul S, Roblin X. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor. Aliment Pharmacol Ther. 2018 Apr;47(8):1117-1125. https://pubmed.ncbi.nlm.nih.gov/29446098/
Yacoub W, Williet N, Pouillon L, Di-Bernado T, De Carvalho Bittencourt M, Nancey S, Lopez A, Paul S, Zallot, Roblin X, Peyrin-Biroulet L. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther. 2018 Jan 31. https://pubmed.ncbi.nlm.nih.gov/29384209/
Gouynou C, Pouillon L, Rousseau H, Zallot C, Baumann C, Peyrin-Biroulet L. Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation. Gut. 2018 Jan 13.  https://pubmed.ncbi.nlm.nih.gov/29331941/
Williet N, Boschetti G, Fovet M, Di Bernado T, Claudez P, Del Tedesco E, Jarlot C, Rinaldi L, Berger A, Phelip JM, Flourie B, Nancey S, Paul S, Roblin X. Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases With Need for Additional Doses Within 6 months. Clin Gastroenterol Hepatol. 2016 Nov 24.